Key Takeaways
- • Blackstone and TPG completed the acquisition of Hologic on April 7, 2026, valuing the transaction at up to $79 per share, with stockholders receiving $76 in cash plus a non-tradable contingent value right (CVR) worth up to $3 per share in two installments.
- • The total transaction value reached approximately $17.3–$18 billion, establishing Hologic as a private company and marking the end of its public trading period on NASDAQ under ticker HOLX.
- • CVR payments are contingent on Hologic meeting specific Breast Health revenue targets during 2026 and 2027, creating uncertainty around the maximum per-share payout and requiring performance-based milestone achievement.
- • Strategic minority investments from Abu Dhabi Investment Authority (ADIA) and GIC affiliate provide significant capital partners alongside Blackstone and TPG, signaling confidence in Hologic's growth trajectory under private ownership.
- • José (Joe) E. Almeida was appointed Chief Executive Officer effective immediately upon deal completion, replacing prior leadership as the company transitions to a private equity-backed operating structure focused on innovation and women's health initiatives.
Summary
Blackstone and TPG successfully completed their acquisition of Hologic, Inc. on April 7, 2026, transitioning the global women's health medical technology company from public to private ownership. The transaction was valued at up to $79 per share, with Hologic stockholders entitled to receive $76 per share in cash alongside a non-tradable contingent value right (CVR) structured to deliver up to $3 per share in two separate payments of $1.50 each. The deal's total enterprise value reached approximately $17.3 to $18 billion, representing a significant consolidation of one of the medical device industry's most recognizable diagnostics and imaging platforms.
The CVR component introduces performance-based conditionality into shareholder returns, contingent on Hologic achieving specified Breast Health revenue milestones during fiscal 2026 and 2027. This structure incentivizes management to drive revenue growth in the company's highest-margin diagnostic imaging segment while potentially capping downside protection if targets are missed. The contingent nature of CVR payments distinguishes this deal from a fully cash-certain takeout, requiring investors to monitor Hologic's operational execution against pre-agreed financial benchmarks through the earn-out period.
The acquisition was initially announced on October 21, 2025, and received stockholder approval on February 5, 2026, clearing the final regulatory and corporate governance hurdles for closure. Beyond Blackstone and TPG's lead investor roles, the transaction secured significant minority capital commitments from Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC, positioning these sovereign wealth funds as long-term stakeholders in Hologic's post-acquisition strategy. This international institutional backing reflects confidence in the private equity sponsors' operational thesis and the company's market position.
Leadership transition accompanied the deal closure, with José (Joe) E. Almeida appointed Chief Executive Officer effective immediately following transaction completion. Almeida's appointment signals a strategic shift toward growth-oriented operations and innovation investment under private equity stewardship, replacing the prior public company management structure that had operated since 2013. Hologic, headquartered in Marlborough, Massachusetts, generated approximately $4.1 billion in fiscal 2025 revenues while maintaining a 31.2% non-GAAP operating margin, providing a strong profitability foundation for the new private ownership structure's value creation agenda focused on women's health diagnostics, breast imaging, gynecological surgical solutions, and skeletal health offerings.
The CVR component introduces performance-based conditionality into shareholder returns, contingent on Hologic achieving specified Breast Health revenue milestones during fiscal 2026 and 2027. This structure incentivizes management to drive revenue growth in the company's highest-margin diagnostic imaging segment while potentially capping downside protection if targets are missed. The contingent nature of CVR payments distinguishes this deal from a fully cash-certain takeout, requiring investors to monitor Hologic's operational execution against pre-agreed financial benchmarks through the earn-out period.
The acquisition was initially announced on October 21, 2025, and received stockholder approval on February 5, 2026, clearing the final regulatory and corporate governance hurdles for closure. Beyond Blackstone and TPG's lead investor roles, the transaction secured significant minority capital commitments from Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC, positioning these sovereign wealth funds as long-term stakeholders in Hologic's post-acquisition strategy. This international institutional backing reflects confidence in the private equity sponsors' operational thesis and the company's market position.
Leadership transition accompanied the deal closure, with José (Joe) E. Almeida appointed Chief Executive Officer effective immediately following transaction completion. Almeida's appointment signals a strategic shift toward growth-oriented operations and innovation investment under private equity stewardship, replacing the prior public company management structure that had operated since 2013. Hologic, headquartered in Marlborough, Massachusetts, generated approximately $4.1 billion in fiscal 2025 revenues while maintaining a 31.2% non-GAAP operating margin, providing a strong profitability foundation for the new private ownership structure's value creation agenda focused on women's health diagnostics, breast imaging, gynecological surgical solutions, and skeletal health offerings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.